|H.Jim, thanks for the link.|
As a BMY long SH (not very happy for last 18 months), I can only say that I am even less happy now with CELG deal. And, there is several reasons that I think that they overpaid for this deal. First BMY has several bad deals of late, and sugar over everything is CELG deal.
CELG IMIDs are slowly loosing strain, and IP will eat them inside out. Last 3 large deal, RCPT, Impact, and JUNO, (~$20B in total) are with questionable outcome. Ozanimod and Fedratinib are nothing more than me-too copy of current standard, while JUNO advantage over KITE is maybe nothing more than science-fiction. So, management that grounded CELG are now awarded with this lucrative deal. What message this send true bio-sector? We are ALL winners?????